Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose)

D. V. Do, Y. J. Sepah, D. Boyer, D. Callanan, R. Gallemore, M. Bennett, D. M. Marcus, L. Halperin, M. A. Sadiq, N. Rajagopalan, P. A. Campochiaro, Q. D. Nguyen

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Purpose To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME) and a central subfield thickness (CFT) of ≥250 μm on time-domain optical coherence tomography.Design Randomized, controlled, multicenter clinical trial.MethodsEligible eyes were randomized in a 1:1 ratio to 0.5 mg (n=77) or 2.0 mg (n=75) RBZ. Study eyes received 6-monthly injections.Main outcome measuresThe primary outcome measure was the mean change in best corrected visual acuity (BCVA) at month 6. Secondary outcomes included the incidence and severity of systemic and ocular adverse events and the mean change in CFT from baseline.ResultsIn all, 152 eyes (152 patients) were randomized in the study. At month 6, the mean improvement from baseline BCVA was +9.43 letters in the 0.5 mg RBZ group and +7.01 letters in the 2.0 mg RBZ group (P=0.161). At month 6, one death occurred in the 0.5 mg RBZ group and three deaths in the 2.0 mg RBZ group, all due to myocardial infarction in subjects with a prior history of heart disease. Mean CFT was reduced by 168.58 μm in the 0.5 mg RBZ group and by 159.70 μm in the 2.0 mg RBZ group (P=0.708).ConclusionsThere was no statistically significant difference in the mean number of letters gained between the 0.5 and 2.0 mg RBZ groups through month 6. In this DME study population, high-dose RBZ does not appear to provide additional benefit over 0.5 mg RBZ.

Original languageEnglish (US)
Pages (from-to)1538-1544
Number of pages7
JournalEye (Basingstoke)
Volume29
Issue number12
DOIs
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Fingerprint Dive into the research topics of 'Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose)'. Together they form a unique fingerprint.

  • Cite this

    Do, D. V., Sepah, Y. J., Boyer, D., Callanan, D., Gallemore, R., Bennett, M., Marcus, D. M., Halperin, L., Sadiq, M. A., Rajagopalan, N., Campochiaro, P. A., & Nguyen, Q. D. (2015). Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). Eye (Basingstoke), 29(12), 1538-1544. https://doi.org/10.1038/eye.2015.142